The dangers of biotech investing were on display on Wednesday as Amplia Therapeutics (ASX:ATX), developing a cancer treatment called ACCENT, failed to meet market expectations on the Wednesday session.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
While many on the HotCopper forums were perhaps contrarian, optimistic about the news, there is one note to make about the company’s topline trial data results.
(Worth noting, that means there’s more thorough data coming later – in Q1 of 2026.)
But for now, the company ran with one observation – ACCENT, referring to the drug narmafotinib, adds another two months of life expectancy to patients with the target cancer using chemo alone.
On a bourse full of small biotechs pushing cancer treatments ultimately designed to be used in conjunction with chemotherapy drugs, clearly, at least one cohort of ATX investors has shrugged at a two-month survival boost and jumped ship.
Still, the company reported its drug was well tolerated and that progress is still on track for a “pivotal phase 2b/3 trial” in the second half of next year, which would be the penultimate study ahead of a potential regulatory approval, all cards in order.
Still, for now, the signal of Wednesday’s price action suggests some were perhaps hoping for a more meaningful longevity proposition for patients.
The company also referenced an adverse event profile no worse than what other adverse events are experienced using more common chemo combinations, but described these as “rare.”
More market news
Put the scissors away: Bullock tames RBA cut hopes – and apparently that’s a surprise
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
A total of seven patients continued to participate in the trial for more than a year – but that 12-months-for-two-months trade-off could be forming part of downside calculus.
ATX last traded at 18cps.
Join the discussion: See what HotCopper users are saying about Amplia Therapeutics Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.